Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

• Sponsor: Stanford University (Other)
• Overall Status: Completed
• CT.gov ID: NCT00398372
• Collaborator: Amgen (Industry), National Institutes of Health (NIH) (NIH)
• Enrollment: 500
• Location: 1
• Duration (Months): 106
• Patients Per Site Per Month: 4.7

Study Details

Study Description

Brief Summary

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Condition or Disease	Intervention/Treatment	Phase
Lymphoma, Non-Hodgkin; Lymphomas: Non-Hodgkin; Lymphomas: Non-Hodgkin Cutaneous Lymphoma; Lymphomas: Non-Hodgkin Diffuse Large B-Cell; Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell; Lymphomas: Non-Hodgkin Mantle Cell; Lymphomas: Non-Hodgkin Marginal Zone; Lymphomas: Non-Hodgkin Peripheral T-Cell; Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia	Drug: Rituximab; Drug: Epratuzumab	N/A

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 500 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Official Title: Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
• Study Start Date: Nov 1, 2000
• Actual Primary Completion Date: Jun 1, 2007
• Actual Study Completion Date: Sep 1, 2009

Outcome Measures

Primary Outcome Measures

1. To characterize the molecular and cell biology of the tumor cells in lymphoma. [6 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Stanford University School of Medicine	Stanford	California	United States	94305

Sponsors and Collaborators

• Stanford University
• Amgen
• National Institutes of Health (NIH)

Investigators

• Principal Investigator: Wen-Kai Weng, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00398372
• Other Study ID Numbers: LYMNHL0031; 200114861; 77550; CA09287; CA111827; LYMNHL0031
• First Posted: Nov 10, 2006
• Last Update Posted: Jun 2, 2011
• Last Verified: Jul 1, 2010

• Additional relevant MeSH terms: Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Rituximab; Epratuzumab

Study Results

No Results Posted as of Jun 2, 2011